MYELOFIBROSIS TRANSFORMATION IN ESSENTIAL THROMBOCYTHEMIA
Clinical trials for MYELOFIBROSIS TRANSFORMATION IN ESSENTIAL THROMBOCYTHEMIA explained in plain language.
Never miss a new study
Get alerted when new MYELOFIBROSIS TRANSFORMATION IN ESSENTIAL THROMBOCYTHEMIA trials appear
Sign up with your email to follow new studies for MYELOFIBROSIS TRANSFORMATION IN ESSENTIAL THROMBOCYTHEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug trial targets scarring bone marrow disease
Disease control OngoingThis study is testing if a drug called elotuzumab can help control myelofibrosis, a rare blood cancer that causes bone marrow scarring. The trial will involve about 15 adults with a specific genetic change (JAK2 mutation) who are not candidates for standard JAK inhibitor therapy.…
Matched conditions: MYELOFIBROSIS TRANSFORMATION IN ESSENTIAL THROMBOCYTHEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Two-Pronged attack on rare blood cancers shows promise
Disease control OngoingThis study is testing whether combining two existing drugs, ruxolitinib and azacytidine, is a better treatment for people with myelofibrosis and related blood cancers. The trial enrolled 121 patients to see if this combination can improve their disease status more effectively tha…
Matched conditions: MYELOFIBROSIS TRANSFORMATION IN ESSENTIAL THROMBOCYTHEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC